Neuberger Berman Canada’s Teva Pharmaceuticals TEVA Stock Holding History

Neuberger Berman Canada’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-19,000	Closed	-$631K	–	357
2017 Q2	$631K	Sell	19,000 -35,224	-65%	-$1.09M	0.12%	236
2017 Q1	$1.74M	Sell	54,224 -10,619	-16%	-$362K	0.34%	61
2016 Q4	$2.35M	Buy	64,843 +39,140	+152%	+$1.56M	0.59%	27
2016 Q3	$1.18M	Sell	25,703 -3,181	-11%	-$166K	0.36%	63
2016 Q2	$1.45M	Buy	28,884 +3,667	+15%	+$195K	0.47%	47
2016 Q1	$1.35M	Buy	+25,217	New	+$1.48M	0.5%	54

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Neuberger Berman Canada's TEVA Position: Q3 2017 in Review

Neuberger Berman Canada sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 19,000 shares — an estimated $631K sold.

Neuberger Berman Canada first reported a position in TEVA in Q1 2016 and held it in 6 quarters. The position peaked at $2.35M in Q4 2016. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Neuberger Berman Canada reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Neuberger Berman Canada sold 19,000 Teva Pharmaceuticals shares in Q3 2017, an estimated $631K.
Neuberger Berman Canada first reported a position in Teva Pharmaceuticals in Q1 2016 and held it in 6 quarters.
Neuberger Berman Canada's Teva Pharmaceuticals position peaked at $2.35M in Q4 2016.
535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Neuberger Berman Canada's 13F filing for Q3 2017, filed 3 Nov 2017.